GemOx方案治疗晚期复发转移卵巢癌的疗效观察.docVIP

GemOx方案治疗晚期复发转移卵巢癌的疗效观察.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
GemOx方案治疗晚期复发转移卵巢癌的疗效观察

GemOx方案治疗晚期复发转移卵巢癌的疗效观察 【摘要】目的:探讨GemOx方案(吉西他滨联合奥沙利铂)治疗晚期复发转移卵巢癌的疗效及不良反应。方法:共入组22例患者, 其中铂类敏感复发转移12例,铂类耐药复发转移10例。所有患者均予吉西他滨1 000 mg/m2第1,8天静脉给药;奥沙利铂130 mg/m2,第1天静脉给药。3周为1周期,每个患者至少接受2周期化疗用药。每2个周期后评价疗效、临床受益反应及不良反应。结果:共完成82个化疗周期,可评价疗效的21例,有效率为31.8%,铂类敏感患者中,有效率为41.7%,铂类耐药为20.0%;临床受益反应率为57.1%;主要毒性反应为骨髓抑制和神经毒性, 白细胞减少15例(68.2%),血小板减少16例(72.7%),神经毒性、感觉异常达71.4%。结论:GemOx方案治疗晚期复发转移卵巢癌患者是有效的, 毒性反应可以耐受,生存质量明显提高。 【关键词】 海南省人民医院 肿瘤内科,海南 海口 570311 Effect of gemcitabine and oxaliplatin on recurrent advanced ovarian carcinomaWANG Lin, XIE Xianhe, MAI Zefeng, WANG Wei, XING Xuehua(Department of Oncology, Peoplersquo;s Hospital of Hainan Province Haikou 570311, China )[ABSTRACT] Objective: To evaluate the effects of gemcitabine and oxaliplatin(GemOx) on recurrent advanced ovarian carcinoma and its adverse reactions. Methods: A total of 22 patients with recurrent advanced ovarian carcinoma were enrolled, including 12 patients of platinumsensitive and 10 patients of platinumresistant. All patients were treated with gemcitabine 1 000 mg/m2 intravenously at 1, 8 days and oxaliplatin 130 mg/m2 intravenously at first day; 3 weeks was 1 cycle; each patient received at least 2 cycles of chemotherapy. Efficacy, clinical benefit response and adverse reactions were evaluated every two cycles. Results: A total of 82 cycles of chemotherapy were completed; 21 cases received evaluation of efficacy, and the effective rate was 31.8%; the effective rate for platinumsensitive and platinumresistant patients was 41.7% and 20.0% respectively; clinical benefit response rate was 57.1%; the main toxicity was bone marrow depression and neurological toxicity, 15 cases occurred leukopenia (68.2%), 16 cases occurred thrombocytopenia(72.7%), 71.4% patients occurred neurotoxicity and sensory abnormalities. Conclusion: Treatment of recurrent advanced ovarian cancer with GemOx is effective, the toxicity is tolerable, and the quality of life was improved markedly. [KEY WORDS]Ovarian tumor; Cancer; Drug therapy; Ge

文档评论(0)

jgx3536 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

版权声明书
用户编号:6111134150000003

1亿VIP精品文档

相关文档